Nitric Oxide Synthases Activation and Inhibition by Metallacarborane-Cluster-Based Isoform-Specific Affectors

Robert Kaplánek,[†] Pavel Martásek,[‡,§] Bohumír Grüner,[∥] Satya Panda,[⊥] Jakub Rak,[†] Bettie Sue Siler Masters,[⊥] Vladimír Král,*[,†,∞] and Linda J. Roman*[,⊥]

[†]Department of Analytical Chemistry, Institute of Chemical Technology in Prague, Technická 5, 166 28 Prague 6, Czech Republic
[‡]First Faculty of Medicine, Charles University in Prague, Kateřinská 32, 121 08 Prague 2, Czech Republic
[§]University General Hospital, 128 08 Praha 2, Czech Republic
[∥]Institute of Inorganic Chemistry, Academy of Sciences of the Czech Republic, Area of Research Institutes 1001, 250 68 Husinec, Řež u Prahy, Czech Republic
[⊥]Department of Biochemistry, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, United States
[∞]Zentiva R&D, Part of Sanofi-Aventis, U Kabelovny 130, 102 37 Prague 10, Czech Republic

ABSTRACT: A small library of boron-cluster- and metallacarborane-cluster-based ligands was designed, prepared, and tested for isoform-selective activation or inhibition of the three nitric oxide synthase isoforms. On the basis of the concept of creating a hydrophobic analogue of a natural substrate, a stable and nontoxic basic boron cluster system, previously used for boron neutron capture therapy, was modified by the addition of positively charged moieties to its periphery, providing hydrophobic and nonclassical hydrogen bonding interactions with the protein. Several of these compounds show efficacy for inhibition of NO synthesis with differential effects on the various nitric oxide synthase isoforms.

$C_4H_{18}B_{18}Co^-$

■ INTRODUCTION

Nitric oxide (NO) is a biological messenger produced by the nitric oxide synthases (NOSs) and is involved in many physiological processes serving a variety of regulatory and immunological functions. The mammalian NOS family consists of three isoforms, neuronal NOS (nNOS or NOSI), inducible NOS (iNOS or NOSII), and endothelial cell NOS (eNOS or NOSIII). All isoforms are homodimers that catalyze the NADPH-dependent oxidation of L-arginine to L-citrulline and nitric oxide. The three NOS isoforms play unique, separate, and characteristic roles in various tissues and cell types; the NO produced has been implicated in such varied processes as neurotransmission, the immune response, and hemodynamic control (for review, see refs 1−8).

Overproduction of NO by nNOS and iNOS has been implicated in ischemic injury following strokes, migraine headaches, autoimmune diseases such as rheumatoid arthritis and ulcerative colitis, Parkinson's and Alzheimer's diseases, liver cirrhosis, inflammation, and hypotension and vascular leakage during septic shock. Underproduction of NO by eNOS has been implicated in hypertension, atherosclerosis, and endothelial dysfunction. Clearly, the ability to selectively inhibit nNOS and iNOS, but not eNOS, has great potential in developing treatments for these diseases.

Regulation of NO production, with an emphasis on inhibition, is one of the leading themes in NOS biochemistry

and structural biology. To date, many NOS inhibitors have been described, but from a structural point of view, only several tectons have been used for their construction, i.e., arginine and several other amino acid derivatives, amidines, pyridines, urea and thiourea derivatives, indazole derivatives, and oligopeptides.[9−20] Applied structural motifs for the construction of NOS inhibitors have recently been reviewed.[21]

From a physiological point of view, the final goal is to achieve isoform-specific inhibition. The challenge is to come up with a design for a protein-specific compound and the synthetic methodology to create it. On the basis of X-ray-structural analysis of individual NOS isoforms, it is evident that the design and the construction of isoform-specific inhibitors should rely on the molecular recognition of a region of the protein proximate to the binding site of its natural substrate. A search for other types of unconventional chemical structures that would fit into the NOS binding site, be biologically stable, and enable facile chemical modification identified several groups of inorganic compounds, icosahedral boranes, carboranes, and metallacarboranes as promising frameworks for a novel class of non-peptide protein inhibitors.[22,23] These boron clusters are polyhedra based on a three-dimensional skeleton with triangular facets.[22,23] Boron cluster derivatives (boranes,

**Figure 1.** Structures of tested boron cluster derivatives.

carboranes, metallacarboranes) are of interest, as they have been rigorously studied because of their use in boron neutron capture therapy[24−29] and in radioimaging.[28−31] There are now a few examples in the literature of the use of carboranes as stable hydrophobic pharmacophores,[22,23,32] namely, enzyme inhibitors (HIV-1 protease,[33−35] cyclooxygenase,[36,37] serine protease,[38] or protein kinase C[28,39,40]). Structurally, the variety of the known types of boranes, heteroboranes, and metallacarboranes provides an interesting alternative to organic compounds, particularly aromatics. The icosahedral cage is slightly larger than the space occupied by a rotating phenyl ring; metallacarboranes consisting of two eleven-vertex dicarbollide subclusters sandwiching the central metal atom[41] occupy approximately the same volume as a rotating anthracene ring. Among metallacarboranes, the cobalt bis(1,2-dicarbollide)

ion is unique because of its synthetic availability, wide possibilities of exoskeletal modifications, high stability, charge delocalization, low nucleophilicity, strong acidity of conjugated acids, high hydrophobicity, unique solution properties, and ion-pairing behavior.[41−52]

The great potential seen with boron clusters as pharmacophores promoted our venture to this area in the search of NOS inhibitors. Many new molecular systems based on two or more hydrophobic anions covalently bound together by simple or more sophisticated organic bridging moieties have been prepared and tested over the past several years.

Here we report a novel approach toward the development of isoform-specific inhibitors of NOS based on the application of properly substituted boron clusters. This non-natural, resistant-to-catabolism, nontoxic class of compounds represents a very

Scheme 1. Preparation of Derivatives 15−30 via Nucleopholic Dioxane Ring-Opening Reaction of 14

Nucleophiles:

NaOH Hydroxide

NH₃ Ammonia

Thiourea · Guanidine · Diaminoguanidine · 2-Aminoimidazole

Butylamine · Thiosemicarbazide · Aminoguanidine · Urea · 2-(1H-Imidazol-2-yl)-ethylamine

2-(Dimethylamino)-ethanethiol · Girard's reagent T · Acetamidine · L- and D-arginine

interesting scaffold for the construction of a novel class of NOS inhibitors.

The structures of the designed inhibitors are shown in Figure 1. This design allows variation of size, shape, and proper peripheral structural modification for the construction of novel compounds for specific NOS interaction. The intention was to attach known NOS binding motifs, like guanidine, urea, thiourea, aminoguanidine, imidazole, or substituted amine binding groups to the boron cluster periphery, allowing for creation of a variety of compounds with the potential to inhibit NOS. The compounds generated were variations of the boron cluster type, metallacarborane clusters, with a positive charge on the periphery (protonated amino group, quaternary ammonium, guanidinium, aminoguanidinium, thiouronium salts) with various lengths of spacer between the positively charged peripheral functionality (primary interaction site) and the 3D boron cluster.

Synthetic results will be discussed along with spectroscopic results, solubility, and other physicochemical properties of the new compounds. The results obtained indicate high efficacy of several lead structure types as inhibitors of NOS, with IC_{50} values from in vitro experiments lying in the 1−5 μM range.

■ RESULTS AND DISCUSSION

Compounds **15−30** were prepared by nucleophilic dioxane ring-opening reaction of 8-dioxane-3-cobalt bis(dicarbollide) (**14**) with various nucleophiles. This general procedure has already become a routine method for attachment of the cobalt bis(dicarbollide) moiety to a substance via a diethylene glycol spacer.[33−35,43,48−52] If the nucleophile is an anion, the reaction produced anionic derivative (compounds **15** and **18**). In the case of uncharged or thiourea-type nucleophiles, betain-type zwitterions are formed (compounds **16, 17, 19−30**). Syntheses of compounds **15−30** are shown in Scheme 1.

Recent quantum chemical studies showed that boron clusters exhibit specific and well-characterized nonclassical dihydrogen bonding interactions with peptide backbones and functionalities.[32,53] Metallacarborane derivatives usually display very low aqueous solubility and spontaneous self-assembling that are caused by their hydrophobicity. Self-assembling of metallacarboranes in aqueous solution is time-dependent. Fortunately, self-assembly can be easily suppressed by use of suitable biocompatible excipients or by dilution of their DMSO solution, which can also serve as solubility enhancing agents.[51,52] For this reason, solutions of metallacarboranes were used immediately after preparation. We also used their mixtures with heptakis(2,6-di-O-methyl)-β-cyclodextrin (DIMEB), which are stable in time, and boron clusters do not aggregate and/or precipitate.[52] In a biological system, serum albumin can serve as an excipient.[52]

The high degree of similarity between the arginine-binding sites of the NOS isoforms[54−58] makes design of highly selective inhibitors targeted to this region difficult. Our approach is based on the concept of affinity variations in the NOS isoforms *outside the binding cavity*, where X-ray structure analysis reveals the most differences, rather than within the substrate-binding site. To this end, a library of compounds was generated, where the same basic binding motif targeted to the arginine binding site is combined with a variety of boron cluster structural motifs based on borane, carborane, and metallacarborane compounds that would presumably interact with regions in proximity to, but outside of, the substrate-binding site, where real differences between the NOS isoforms may exist. The same or modified binding groups as in the natural substrate were used, but arginine was avoided as the core structure in most of the compounds to prevent unwanted interactions with other arginine-utilizing enzymes. Arginine transport or metabolizing proteins, like dimethylarginine dimethylaminohydrolase (DDAH), arg-gly amidiniotransferase, arginase, argininosucci-

Table 1. Inhibition of NO Synthesis by 20, 22, 23, and 26[a]

	IC$_{50}$ (μM)			selectivity ratio	
	iNOS	nNOS	eNOS	eNOS/iNOS	eNOS/nNOS
20	4.6 ± 0.33	34.6 ± 9.9	39.2 ± 9.2	8.5	1.1
22	1.8 ± 0.18	19.9 ± 7.6	9.1 ± 3.8	5.1	0.46
23	2.6 ± 0.18	13.7 ± 3.3	22.6 ± 3.6	8.7	1.6
26	4.7 ± 0.70	13.8 ± 2.1	38.2 ± 10.6	8.1	2.8

[a]The reported IC$_{50}$ values are ±SE. Selectivity ratios of eNOS to the other isoforms are also reported.

nate synthase, and peptide deiminases, might also recognize inhibitors with close structural similarity to arginine.

NO synthesis assays were performed under direct, competitive, or noncompetitive conditions without benefit of preincubation. This experimental protocol was designed to detect interactions with the heme- and/or flavin-binding domains. The parent compounds **10** and **11** (structures shown in Figure 1) displayed no inhibition of NOS activity. When conjugated with a guanidine group (compounds **12** and **13**) as a substrate analogue, however, these compounds (at 10 μM) completely inhibited all NOS activity, albeit in a nonspecific manner. Thus, preliminary exploration of these structures has produced compounds that show potential for being modified even further to produce potent, highly specific inhibitors of the NOS isoforms. The IC$_{50}$ values of several of these compounds containing such further modifications obtained with nNOS, eNOS, and iNOS using the hemoglobin capture assay to measure NO production are listed in Table 1 (for compounds **20**, **22**, **23**, and **26**). Other compounds (**1−11**, **15−19**, **21**, **24**, **25**, and **27−30**) display no significant inhibition of NOS activity.

These data clearly show the differential effects of compounds **20** and **23** on the catalysis of NO formation by the three NOS isoforms. As can be seen by comparison with the unsubstituted boron-cage compounds, these substituted structures hold promise for inhibition of NOS activity as appropriate linkers and functional groups (in these cases, thiourea and amino-guanidine groups, respectively) are added to the basic cages.

To confirm that binding of these metallacarborane compounds was actually occurring with binding affinities approximating the catalytic IC$_{50}$ values, fluorescence binding experiments were performed. The representative data shown in Figure 2 illustrate that binding of **22** by iNOS is biphasic and confirm that it is in the same concentration range as that obtained in the IC$_{50}$ determinations, 3.66 and 1.8 μM, respectively (data fit to eq 1 in Experimental Methods).

These studies are preliminary, and these "proof-of-principle" experiments show promise for leading to efficacious differential inhibitors. We have demonstrated that boron clusters represent convenient building blocks that can create important interactions with hydrophobic patches of the NOS binding site. Exoskeletal substitution of the parent metallacarborane compounds introduces additional noncovalent interactions leading to dramatic improvement in inhibition efficacy and selectivity. The combination of the hydrophobic interactions of the scaffold with substitutions allowing for specific dihydrogen bonding and Coulombic interactions might further increase the potency of this novel class of non-peptide NOS inhibitors based on an inorganic framework. As these compounds are very stable, exhibit low toxicity, and enable the introduction of modified side groups, they are extremely attractive prospects for development into much more specific inhibitors of the NOS isoforms.


Figure 2. Quenching of the intrinsic fluorescence of iNOS by **22**. [**22**] was varied from 0 to 50 μM. The experimental conditions were as follows: excitation = 280 nm; emission = 330 nm; [Tris-HCl] = 50 mM; NaCl = 100 mM; pH 7.5 at 25 °C. The fitted line passing through the data is from eq 1 as described in Experimental Methods. Other reaction conditions are also described.

■ CONCLUSIONS

We have identified metallacarboranes (cobalt bis(dicarbollide) derivatives) as a novel structural motif for the construction of isoform-specific NOS activators and/or inhibitors. The potential of these compounds relies on their stability, easy exoskeletal substitution, and spectroscopic properties. The boron cluster compounds thus represent a novel class of NOS activators and/or inhibitors, depending on peripheral substitution of a boron cluster compound, and differ substantially from the organic ones in their constructions and structures.

■ EXPERIMENTAL METHODS

Chemicals. Chemicals used are as follows: (6R)-5,6,7,8-tetrahydrobiopterin was from Research Biochemicals International (Natick, MA). Sodium chloride was from EMD Chemicals, Inc. (Darmstadt, Germany). 8-Dioxane-3-cobalt bis(1,2-dicarbollide)[14] were purchased from Katchem Ltd., Czech Rep. All other chemicals and solvents were purchased from Sigma-Aldrich and were of the highest grade available.

Characterization of Compounds. ^{1}H and ^{11}B NMR spectroscopy experiments were performed using a Varian Gemini 500 HC instrument using DMSO-d_6 as solvent and tetramethylsilane as internal standard for ^{1}H NMR and BF$_3$·Et$_2$O as external standard for ^{11}B NMR, respectively. Chemical shifts are quoted in parts per million (δ scale; s = singlet, d = doublet, m = multiplet) and coupling constants J in Hz. Mass spectrometry measurements were performed on a Bruker Esquire 3000 instrument using electrospray ionization (MS-ESI). Negative ions were detected. The purity of the prepared compounds was determined by elemental analysis and liquid

chromatography (coupled with MS-ESI). All compounds have purity of ≥97%.

Enzymes. The neuronal, endothelial, and inducible isoforms of NOS were expressed and purified as previously described.[59−62] Calmodulin was prepared by the method of Zhang and Vogel.[63]

Inhibition Assays. The generation of nitric oxide was measured at 23 °C by the Hb capture method[64] on a Molecular Dynamics VERSAmax microplate reader in flat-bottom 96-well plates with a path length of 0.72 cm. Inhibitors (10 μM) plus 100−200 nM nNOS, iNOS, or eNOS were assayed in 8 μM oxy Hb, 25 μM L-arginine, 50 μM Ca^{2+}, 1 μM CaM, 5 μM BH$_4$, and 100 μM NADPH in 50 mM Tris-HCl, 100 mM NaCl, pH 7.5, in a total volume of 0.3 mL. A mixture of oxy Hb, L-arginine, Ca^{2+}, and CaM was added to each well with a multichannel pipet, while inhibitor, NOS, and BH$_4$ were added individually from a single container in an effort to prevent degradation. The reaction was started with the addition of 100 μM NADPH, and the change in aborbance at 401 nm was measured every 3 s for 1 min. The extinction coefficient used to calculate the rates was 60 mM^{-1}. Only compounds that showed a differential inhibition of NOS isoforms were chosen for determination of IC$_{50}$ values.

Fluorescence Study. The fluorescence spectra of iNOS were recorded at 25 °C using a Fluorolog-3 (Jobin Yvon-Spex, Edison, NJ) spectrofluorometer. Excitation was at 280 nm (path length, 0.5 mm; slit, 2 nm band-pass), and emission was recorded in the range 250−450 nm (path length, 0.2 mm; 2 nm band-pass). Buffer (50 mM Tris-HCl, 100 mM NaCl, pH 7.5 at 25 °C) was filtered using 0.2 μm Corning filters and degassed. Intensities at the emission maximum of 330 nm did not show any observable shifts as the concentration of the compound was increased by titrating in microliter volumes of concentrated stock solution into the protein solution. The final volume of the added solution was very small and did not cause any significant changes in fluorescence intensities. After trying a variety of models for binding constants,[65] the data fitted best to a two-part equation, with the first term similar to a Hill type equation for binding constants for specific binding and the second part consisting of a straight line.

$$F_{obs} = \frac{F_{min}[S]^n}{K + [S]^n} + ((slope)[S] + intercept) \qquad (1)$$

where F_{obs} is the observed fluorescence intensity of iNOS in the presence of varying concentrations of the compound (0−50 μM), F_{min} is the theoretical minimum of the observed fluorescence intensity, [S] is the compound concentration, n is the Hill coefficient related to the number of binding sites, and K is the apparent binding constant.

Chemical Syntheses. Derivatives **1−11**, **15**, **20**, **22**, and **25** (structures shown in Figure 1) were prepared as described in the literature: **2** and **3**,[45] **4**,[66] **5**,[67] **6**,[68] **7**,[69] **8**,[46] **9**,[70] **10**,[71] **11**,[72,73] **15**,[74] **20**, **22**, and **25**.[51] Guanidinium derivatives **12** and **13** were prepared from corresponding amino derivatives (**10** and **11**, respectively) by standard guanylation reactions.[75−77]

The synthetic protocol for the preparation of the library of boron cluster inhibitors is shown in Scheme 1, where 8-dioxane-3-cobalt bis(dicarbollide) (**14**) is opened by series of S- and N-nucleophiles. All compounds were verified by elementary analysis, mass spectrometry, and ^{1}H NMR and ^{11}B NMR spectroscopy.

General Method of Preparation of Compounds 15−30. To a stirred slurry of sodium hydride (60% suspension in oil) in anhydrous THF was added S-, O- or salt of N-nucleophile. Reaction mixture was stirred at room temperature for 30−60 min. Then a solution of 8-dioxane-3-cobalt bis(dicarbollide) (**14**) in toluene−THF mixture (3:1 v/v) (molar ratio nucleophile/**14** = 2:1) was added. In the case of neat N-nucleophiles, solution of **14** was added directly to the solution of N-nucleophile. The reaction mixture was heated to 70 °C for 15−60 min (TLC monitoring; eluent, dichloromethane). After the mixture was cooled, water was added and the aqueous phase was extracted with dichloromethane (5 × 50 mL). The combined organic layers were washed with water (20 mL) and brine (20 mL) and dried (MgSO$_4$). After evaporation, the resulting glassy solid was dissolved in CH$_2$Cl$_2$ (5 mL) and precipitated by addition of hexane (30 mL) or purified by

column chromatography on silica (eluent, dichloromethane followed by dichloromethane/acetone, 3:1 to 1:1 v/v). The orange solid product was dried in vacuum at 50 °C.

^{1}H and ^{11}B NMR spectra of compounds **15−30** are similar. ^{1}H NMR (DMSO-d_6) δ: 0.90−4.15 (m, BH and OCH$_2$, NCH$_2$, SCH$_2^{(if present)}$, CH$_2^{(if present)}$ and NH); 4.14 (s, CH$_{carborane}$). Compound **26** additional signal: 6.98 (s, 2H, imidazole-H). Compound **18** additional signal: 2.32 (s, 6H, NMe$_2$), compound **19** additional signal: 3.31 (s, 9H, N$^+$Me$_3$). Compound **27** additional signal: 7.11 (s, 2H, imidazole-H).

^{11}B NMR (DMSO-d_6): δ = −28.3 (d, 1B, B6, $^1J_{(B,H)}$ = 140 Hz); −21.6 (d, 1B, B6′, $^1J_{(B,H)}$ = 171 Hz); −20.4 (d, 2B, B5, B11, $^1J_{(B,H)}$ = 153 Hz); −17.3 (d, 2B, B5′, B11′, $^1J_{(B,H)}$ = 145 Hz); −7.8 to −8.2 (m, 6B, B4, B7, B9, B12, B9′, B12′), −4.3 (d, 2B, B4′, B7′, $^1J_{(B,H)}$ = 153 Hz); −2.5 (d, 1B, B10, $^1J_{B,H}$ = 143 Hz); 0.4 (d, 1B, B10′, $^1J_{(B,H)}$ = 141 Hz); 3.9 (d, 1B, B8′, $^1J_{(B,H)}$ = 142 Hz); 23.3 (s, 1B, B8).

Compound 18: NaH (48 mg, 60% in oil, 1.2 mmol), 2-(dimethylamino)ethanethiol hydrochloride (85 mg, 0.6 mmol), THF (4 mL), then **14** (165 mg, 0.4 mmol), toluene−THF (3:1 v/v, 6 mL). Yield of **18**: 204 mg (95%). Anal. Calcd for C$_{12}$H$_{39}$B$_{18}$CoNNaO$_2$S: C, 26.79; H, 7.31; N, 2.60. Found: C, 26.70; H, 7.40; N, 2.55. MS-ESI m/e: 538.37 (100.0%), 537.38 (100.0%), 539.37 (90.2%), 536.38 (63.3%), 540.36 (34.6%), 535.38 (33.6%), 540.37 (15.4%), 534.39 (15.0%), 538.38 (12.7%), 541.36 (11.4%), 541.37 (6.2%), 533.39 (4.9%), 536.39 (4.8%), 542.36 (2.7%), 535.39 (2.3%), 539.38 (2.2%), 532.39 (1.3%), 540.38 (1.3%), 542.37 (1.0%)

Compound 19: acethydrazide trimethylammonium chloride (Girard's reagent T; 135 mg, 0.8 mmol), **14** (165 mg, 0.4 mmol), THF (12 mL). Yield of **19**: 201 mg (93%). Anal. Calcd for C$_{13}$H$_{42}$B$_{18}$CoN$_3$O$_3$: C, 28.81; H, 7.81; N, 7.75. Found: C, 28.75; H, 7.90; N, 7.73. MS-ESI m/e: 541.44 (100.0%), 542.43 (98.1%), 543.43 (74.4%), 540.44 (63.3%), 544.43 (46.1%), 539.45 (36.1%), 543.44 (15.8%), 538.45 (14.5%), 542.44 (13.4%), 545.42 (8.1%), 545.43 (5.7%), 540.45 (5.1%), 537.45 (4.9%), 544.44 (1.9%), 546.43 (1.7%), 536.46 (1.4%), 542.45 (1.1%).

Compound 20: NaH (16 mg, 60% in oil, 0.4 mmol), thiourea (31 mg, 0.4 mmol), THF (2 mL), then **14** (83 mg, 0.2 mmol), toluene−THF (3:1 v/v, 3 mL). Yield of **20**: 80 mg (82%). Anal. Calcd for C$_9$H$_{33}$B$_{18}$CoN$_2$O$_2$S: C, 22.20; H, 6.83; N, 5.75. Found: C, 22.14; H, 6.79; N, 5.77. MS-ESI m/e: 487.34 (100.0%), 486.34 (84.4%), 488.33 (67.2%), 485.35 (61.2%), 489.33 (36.5%), 484.35 (31.2%), 488.34 (13.8%), 490.33 (13.7%), 483.35 (13.1%), 489.34 (8.0%), 486.35 (6.1%), 482.36 (4.6%), 491.33 (2.7%), 484.36 (1.4%), 481.36 (1.2%), 490.34 (1.2%), 487.35 (1.1%)

Compound 21: NaH (16 mg, 60% in oil, 0.4 mmol), thiosemicarbazide (37 mg, 0.4 mmol), THF (2 mL), then **14** (83 mg, 0.2 mmol), toluene−THF (3:1 v/v, 3 mL). Yield of **21**: 93 mg (92%). Anal. Calcd for C$_9$H$_{34}$B$_{18}$CoN$_3$O$_2$S: C, 21.53; H, 6.83; N, 8.37. Found: C, 21.55; H, 6.80; N, 8.35. MS-ESI m/e: 502.35 (100.0%), 501.35 (89.6%), 503.35 (87.4%), 500.36 (66.4%), 504.34 (39.8%), 499.36 (33.8%), 505.34 (14.9%), 498.36 (14.2%), 502.36 (9.9%), 501.36 (8.6%), 504.35 (8.4%), 497.37 (5.0%), 506.34 (2.8%), 503.36 (1.6%), 499.37 (1.5%), 505.35 (1.4%), 496.37 (1.3%)

Compound 22: NaH (400 mg, 60% in oil, 10 mmol), guanidine hydrochloride (955 mg, 10 mmol), THF (10 mL), then **14** (410 mg, 1 mmol), toluene−THF (3:1 v/v, 3 mL). Yield of **22**: 452 mg (95%).

For guanidine carbonate (900 mg, 5 mmol), THF (20 mL), then **14** (821 mg, 2 mmol). Yield of **22**: 549 mg (58%). Anal. Calcd for C$_9$H$_{34}$B$_{18}$CoN$_3$O$_2$: C, 23.00; H, 7.29; N, 8.94. Found: C, 22.96; H, 7.32; N, 9.00. MS-ESI m/e: 470.38 (100.0%), 469.38 (85.2%), 471.37 (69.5%), 468.38 (59.1%), 472.37 (33.2%), 467.39 (33.1%), 466.39 (13.5%), 473.37 (10.9%), 471.38 (9.7%), 472.38 (7.9%), 469.39 (6.3%), 465.39 (4.6%), 468.39 (3.2%), 464.40 (1.3%)

Compound 23: NaH (240 mg, 60% in oil, 6 mmol), aminoguanidine hemisulfate (738 mg, 6 mmol), THF (10 mL), then **14** (410 mg, 1 mmol), toluene−THF (3:1 v/v, 10 mL). Yield of **23**: 482 mg (98%). Anal. Calcd for C$_9$H$_{35}$B$_{18}$CoN$_4$O$_2$: C, 22.29; H, 7.27; N, 11.55. Found: C, 22.31; H, 7.30; N, 11.56. MS-ESI m/e: 485.39 (100.0%), 484.39 (85.2%), 486.38 (69.7%), 483.39 (58.7%), 487.38 (33.4%), 482.40 (31.8%), 481.40 (13.5%), 488.38 (11.0%), 486.39 (9.4%),

487.39 (7.9%), 484.40 (6.2%), 480.41 (4.7%), 483.40 (3.7%), 482.41 (1.4%), 479.41 (1.3%), 485.40 (1.0%)

Compound 24: NaH (16 mg, 60% in oil, 0.4 mmol), N,N'-diaminoguanidine hydrochloride (50 mg, 0.4 mmol), THF (2 mL), then **14** (83 mg, 0.2 mmol), toluene−THF (3:1 v/v, 4 mL). Yield of **24**: 94 mg (93%). Anal. Calcd for $C_9H_{36}B_{18}CoN_5O_2$: C, 21.62; H, 7.26; N, 14.01. Found: C, 21.68; H, 7.33; N, 13.98. MS-ESI m/e: 500.40 (100.0%), 499.40 (92.8%), 501.39 (74.2%), 498.41 (67.7%), 502.39 (36.5%), 497.41 (34.6%), 496.41 (14.7%), 501.40 (12.0%), 503.39 (11.9%), 500.41 (10.0%), 502.40 (8.2%), 499.41 (6.7%), 495.42 (5.2%), 497.42 (1.5%), 494.42 (1.4%)

Compound 26: NaH (48 mg, 60% in oil, 1.2 mmol), 2-aminoimidazole hemisulfate (80 mg, 0.6 mmol), THF (4 mL), then **14** (165 mg, 0.4 mmol), toluene−THF (3:1 v/v, 6 mL). Yield of **26**: 172 mg (87%). Anal. Calcd for $C_{11}H_{34}B_{18}CoN_3O_2$: C, 26.75; H, 6.94; N, 8.51. Found: C, 26.68; H, 6.93; N, 8.45. MS-ESI m/e: 494.38 (100.0%), 493.38 (83.6%), 495.37 (68.2%), 492.38 (58.1%), 491.39 (32.8%), 496.37 (32.6%), 490.39 (13.3%), 495.38 (11.5%), 497.37 (11.4%), 496.38 (9.4%), 493.39 (7.5%), 489.39 (4.5%), 492.39 (3.9%), 488.40 (1.3%), 498.37 (1.1%).

Compound 27: NaH (48 mg, 60% in oil, 1.2 mmol), 2-(1H-imidazol-2-yl)-ethylamine hydrochloride (89 mg, 0.6 mmol), THF (4 mL), then **14** (165 mg, 0.4 mmol), toluene-THF (3:1 v/v, 8 mL). Yield of **27**: 177 mg (85%). Anal. Calcd for $C_{13}H_{38}B_{18}CoN_3O_2$: C, 29.91; H, 7.34; N, 8.05. Found: C, 29.83; H, 7.38; N, 7.43. MS-ESI m/e: 522.41 (100.0%), 521.41 (82.3%), 523.40 (66.1%), 520.42 (61.5%), 524.40 (32.0%), 519.42 (30.7%), 523.41 (13.9%), 518.42 (13.1%), 525.40 (11.9%), 524.41 (10.9%), 521.42 (8.5%), 517.43 (4.6%), 519.43 (2.0%), 522.42 (1.3%), 516.43 (1.2%), 526.40 (1.2%), 523.42 (1.2%), 525.41 (1.1%).

Compound 28: L-arginine (70 mg, 0.4 mmol) in THF (4 mL), then **14** (83 mg, 0.2 mmol), toluene−THF (3:1 v/v, 6 mL). Yield of **28**: 110 mg (94%). Anal. Calcd for $C_{15}H_{45}B_{18}CoN_4O_4$: C, 30.07; H, 7.57; N, 9.35. Found: C, 29.97; H, 7.64; N, 9.40. MS-ESI m/e: 585.44 (100.0%), 584.44 (92.8%), 586.44 (91.2%), 583.45 (69.7%), 587.43 (36.4%), 582.45 (34.6%), 585.45 (15.9%), 581.45 (14.7%), 587.44 (12.8%), 584.45 (10.2%), 588.43 (8.4%), 588.44 (7.2%), 580.46 (5.0%), 582.46 (2.4%), 586.45 (2.4%), 589.43 (1.4%), 579.46 (1.4%), 587.45 (1.3%).

Compound 29: D-arginine (52 mg, 0.3 mmol) in THF (3 mL), then **14** (109 mg, 0.26 mmol), toluene (4 mL). Yield of **29**: 133 mg (86%). Anal. Calcd for $C_{15}H_{45}B_{18}CoN_4O_4$: C, 30.07; H, 7.57; N, 9.35. Found: C, 29.96; H, 7.66; N, 9.36. MS-ESI m/e: 585.44 (100.0%), 584.44 (92.8%), 586.44 (91.2%), 583.45 (69.7%), 587.43 (36.4%), 582.45 (34.6%), 585.45 (15.9%), 581.45 (14.7%), 587.44 (12.8%), 584.45 (10.2%), 588.43 (8.4%), 588.44 (7.2%), 580.46 (5.0%), 582.46 (2.4%), 586.45 (2.4%), 589.43 (1.4%), 579.46 (1.4%), 587.45 (1.3%).

Compound 30: NaH (48 mg, 60% in oil, 1.2 mmol), acetamidine hydrochloride (57 mg, 0.6 mmol), THF (4 mL), then **14** (165 mg, 0.4 mmol), toluene−THF (3:1 v/v, 6 mL). Yield of **30**: 166 mg (88%). Anal. Calcd for $C_{10}H_{35}B_{18}CoN_2O_2$: C, 25.61; H, 7.52; N, 5.97. Found: C, 25.57; H, 7.59; N, 5.93. MS-ESI m/e: 468.39 (100.0%), 469.38 (99.7%), 470.38 (86.2%), 467.39 (64.4%), 471.37 (35.9%), 466.39 (34.7%), 465.40 (15.3%), 469.39 (10.7%), 471.38 (8.5%), 472.37 (8.2%), 464.40 (5.0%), 472.38 (4.8%), 467.40 (4.1%), 466.40 (1.7%), 470.39 (1.5%), 463.40 (1.4%), 471.39 (1.0%).

AUTHOR INFORMATION

Corresponding Author
*For V.K.: phone, +420 724 518 805; e-mail, Vladimir.Kral@vscht.cz. For L.J.R.: phone, 210-567-6979; e-mail, roman@uthscsa.edu.

Notes
The authors declare no competing financial interest.

ACKNOWLEDGMENTS

ABBREVIATIONS USED

NOS, nitric oxide synthase; nNOS, neuronal nitric oxide synthase; eNOS, endothelial nitric oxide synthase; iNOS, inducible nitric oxide synthase; NO, nitric oxide; CaM, calmodulin

REFERENCES

(1) Masters, B. S. In *Nitric Oxide, Biology and Pathobiology*; Ignarro, L. J., Ed.; Academic Press: New York, 2000.

(2) Roman, L. J.; Martásek, P.; Masters, B. S. S. Intrinsic and extrinsic modulation of nitric oxide synthase activity. *Chem. Rev.* **2002**, *102* (4), 1179−1189.

(3) Michel, T.; Feron, O. Nitric oxide synthases: which, where, how, and why? *J. Clin. Invest.* **1997**, *100* (9), 2146−2152.

(4) Alderton, W. K.; Cooper, C. E.; Knowles, R. G. Nitric oxide synthases: structure, function and inhibition. *Biochem. J.* **2001**, *357*, 593−615.

(5) Stuehr, D. J.; Santolini, J.; Wang, Z. Q.; Wei, C. C.; Adak, S. Update on mechanism and catalytic regulation in the NO synthases. *J. Biol. Chem.* **2004**, *279* (35), 36167−36170.

(6) Andrew, P. J.; Mayer, B. Enzymatic function of nitric oxide synthases. *Cardiovasc. Res.* **1999**, *43* (3), 521−531.

(7) Li, H. Y.; Poulos, T. L. Structure−function studies on nitric oxide synthases. *J. Inorg. Biochem.* **2005**, *99* (1), 293−305.

(8) Bruckdorfer, R. The basics about nitric oxide. *Mol. Aspects Med.* **2005**, *26* (1−2), 3−31.

(9) Gomez-Vidal, J. A.; Martásek, P.; Roman, L. J.; Silverman, R. B. Potent and selective conformationally restricted neuronal nitric oxide synthase inhibitors. *J. Med. Chem.* **2004**, *47* (3), 703−710.

(10) Hah, J. M.; Martásek, P.; Roman, L. J.; Silverman, R. B. Aromatic reduced amide bond peptidomimetics as selective inhibitors of neuronal nitric oxide synthase. *J. Med. Chem.* **2003**, *46* (9), 1661−1669.

(11) Hah, J. M.; Roman, L. J.; Martásek, P.; Silverman, R. B. Reduced amide bond peptidomimetics. (4S)-N-(4-Amino-5-[aminoalkyl]-aminopentyl)-N'-nitroguanidines, potent and highly selective inhibitors of neuronal nitric oxide synthase. *J. Med. Chem.* **2001**, *44* (16), 2667−2670.

(12) Huang, H.; Martásek, P.; Roman, L. J.; Masters, B. S. S.; Silverman, R. B. N-omega-Nitroarginine-containing dipeptide amides. Potent and highly selective inhibitors of neuronal nitric oxide synthase. *J. Med. Chem.* **1999**, *42* (16), 3147−3153.

(13) Huang, H.; Martásek, P.; Roman, L. J.; Silverman, R. B. Synthesis and evaluation of peptidomimetics as selective inhibitors and active site probes of nitric oxide synthases. *J. Med. Chem.* **2000**, *43* (15), 2938−2945.

(14) Huang, H.; Martásek, P.; Roman, L. J.; Silverman, R. B. Synthesis and evaluation of dipeptide amides containing N-omega-nitroarginine and D-2,4-diaminobutyric acids as inhibitors of neuronal nitric oxide synthase. *J. Enzyme Inhib.* **2001**, *16* (3), 233−239.

(15) Lee, Y.; Marletta, M. A.; Martásek, P.; Roman, L. J.; Masters, B. S. S.; Silverman, R. B. Conformationally-restricted arginine analogues as alternative substrates and inhibitors of nitric oxide syntheses. *Bioorg. Med. Chem.* **1999**, *7* (6), 1097−1104.

(16) Lee, Y.; Martásek, P.; Roman, L. J.; Masters, B. S. S.; Silverman, R. B. Imidazole-containing amino acids as selective inhibitors of nitric oxide synthases. *Bioorg. Med. Chem.* **1999**, *7* (9), 1941−1951.

(17) Silverman, R. B.; Huang, H.; Marletta, M. A.; Martásek, P. Selective inhibition of neuronal nitric oxide synthase by *N*-omega-nitroarginine- and phenylalanine-containing dipeptides and dipeptide esters. *J. Med. Chem.* **1997**, *40* (18), 2813–2817.

(18) Zhang, H. Q.; Fast, W.; Marletta, M. A.; Martásek, P.; Silverman, R. B. Potent and selective inhibition of neuronal nitric oxide synthase by *N*-omega-propyl-L-arginine. *J. Med. Chem.* **1997**, *40* (24), 3869–3870.

(19) Silverman, R. B. Design of selective neuronal nitric oxide synthase inhibitors for the prevention and treatment of neurodegenerative diseases. *Acc. Chem. Res.* **2009**, *42* (3), 439–451.

(20) Ji, H.; Tan, S.; Igarashi, J.; Li, H.; Derricke, M.; Martásek, P.; Roman, L. J.; Vásquez-Vivar, J.; Poulos, T. L.; Silverman, R. B. Selective neuronal nitric oxide synthase inhibitors and the prevention of cerebral palsy. *Ann. Neurol.* **2009**, *65* (2), 209–217.

(21) Erdal, E. P.; Litzinger, E. A.; Seo, J. W.; Zhu, Y. Q.; Ji, H. T.; Silverman, R. B. Selective neuronal nitric oxide synthase inhibitors. *Curr. Top. Med. Chem.* **2005**, *5* (7), 603–624.

(22) Issa, F.; Kassiou, M.; Rendina, L. M. Boron in drug discovery: carboranes as unique pharmacophores in biologically active compounds. *Chem. Rev.* **2011**, *111* (9), 5701–5722.

(23) Scholz, M.; Hey-Hawkins, E. Carbaboranes as pharmacophores: properties, synthesis, and application strategies. *Chem. Rev.* **2011**, *111* (11), 7035–7062.

(24) Hawthorne, M. F. The role of chemistry in the development of boron neutron-capture therapy of cancer. *Angew. Chem., Int. Ed. Engl.* **1993**, *32* (7), 950–984.

(25) Tjarks, W. The use of boron clusters in the rational design of boronated nucleosides for neutron capture therapy of cancer. *J. Organomet. Chem.* **2000**, *614*, 37–47.

(26) Bregadze, V. I.; Sivaev, I. B.; Glazun, S. A. Polyhedral boron compounds as potential diagnostic and therapeutic antitumor agents. *Anti-Cancer Agents Med. Chem.* **2006**, *6* (2), 75–109.

(27) Crossley, E. L.; Ziolkowski, E. J.; Coderre, J. A.; Rendina, L. M. Boronated DNA-binding compounds as potential agents for boron neutron capture therapy. *Mini-Rev. Med. Chem.* **2007**, *7* (3), 303–313.

(28) Valliant, J. F.; Guenther, K. J.; King, A. S.; Morel, P.; Schaffer, P.; Sogbein, O. O.; Stephenson, K. A. The medicinal chemistry of carboranes. *Coord. Chem. Rev.* **2002**, *232* (1–2), 173–230.

(29) Armstrong, A. F.; Valliant, J. F. The bioinorganic and medicinal chemistry of carboranes: from new drug discovery to molecular imaging and therapy. *Dalton Trans.* **2007**, *38*, 4240–4251.

(30) Hawthorne, M. F.; Maderna, A. Applications of radiolabeled boron clusters to the diagnosis and treatment of cancer. *Chem. Rev.* **1999**, *99* (12), 3421–3434.

(31) Soloway, A. H.; Tjarks, W.; Barnum, B. A.; Rong, F. G.; Barth, R. F.; Codogni, I. M.; Wilson, J. G. The chemistry of neutron capture therapy. *Chem. Rev.* **1998**, *98* (4), 1515–1562.

(32) Lesnikowski, Z. J. Boron units as pharmacophores. New applications and opportunities of boron cluster chemistry. *Collect. Czech. Chem. Commun.* **2007**, *72* (12), 1646–1658.

(33) Cígler, P.; Kožíšek, M.; Řezáčová, P.; Brynda, J.; Otwinowski, Z.; Pokorná, J.; Plešek, J.; Grüner, B.; Dolečková-Marešová, L.; Máša, M.; Sedláček, J.; Bodem, J.; Kräusslich, H. G.; Král, V.; Konvalinka, J. From nonpeptide toward noncarbon protease inhibitors: metallacarboranes as specific and potent inhibitors of HIV protease. *Proc. Natl. Acad. Sci. U.S.A.* **2005**, *102* (43), 15394–15399.

(34) Kožíšek, M.; Cígler, P.; Lepšík, M.; Fanfrlík, J.; Řezáčová, P.; Brynda, J.; Pokorná, J.; Plešek, J.; Grüner, B.; Šašková, K. G.; Václavíková, J.; Král, V.; Konvalinka, J. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance. *J. Med. Chem.* **2008**, *51* (15), 4839–4843.

(35) Řezáčová, P.; Pokorná, J.; Brynda, J.; Kožíšek, M.; Cígler, P.; Lepšík, M.; Fanfrlík, J.; Rezáč, J.; Šašková, K. G.; Sieglová, I.; Plešek, J.; Šícha, V.; Grüner, B.; Oberwinkler, H.; Sedláček, J.; Kräusslich, H. G.; Hobza, P.; Král, V.; Konvalinka, J. Design of HIV protease inhibitors based on inorganic polyhedral metallacarboranes. *J. Med. Chem.* **2009**, *52* (22), 7132–7141.

(36) Scholz, M.; Bensdorf, K.; Gust, R.; Hey-Hawkins, E. Asborin: the carbaborane analogue of aspirin. *ChemMedChem* **2009**, *4* (5), 746–748.

(37) Scholz, M.; Kaluđerović, G. N.; Kommera, H.; Paschke, R.; Will, J.; Sheldrick, W. S.; Hey-Hawkins, E. Carbaboranes as pharmacophores: similarities and differences between aspirin and asborin. *Eur. J. Med. Chem.* **2011**, *46* (4), 1131–1139.

(38) Page, M. F. Z.; Jalisatgi, S. S.; Maderna, A.; Hawthorne, M. F. Design and synthesis of a candidate alpha-human thrombin irreversible inhibitor containing a hydrophobic carborane pharmacophore. *Synthesis* **2008**, *4*, 555–563.

(39) Endo, Y.; Yoshimi, T.; Kimura, K.; Itai, A. Protein kinase C modulators bearing dicarba-closo-dodecaborane as a hydrophobic pharmacophore. *Bioorg. Med. Chem. Lett.* **1999**, *9* (17), 2561–2564.

(40) Tsuji, M.; Koiso, Y.; Takahashi, H.; Hashimoto, Y.; Endo, Y. Modulators of tumor necrosis factor alpha production bearing dicarba-closo-dodecaborane as a hydrophobic pharmacophore. *Biol. Pharm. Bull.* **2000**, *23* (4), 513–516.

(41) Hawthorne, M. F.; Young, D. C.; Wegner, P. A. Carbametallic boron hydride derivatives. I. Apparent analogs of ferrocene and ferricinium ion. *J. Am. Chem. Soc.* **1965**, *87* (8), 1818–1819.

(42) Plešek, J. Potential applications of the boron cluster compounds. *Chem. Rev.* **1992**, *92* (2), 269–278.

(43) Plešek, J.; Heřmánek, S.; Franken, A.; Císařová, I.; Nachtigal, C. Dimethyl sulfate induced nucleophilic substitution of the [bis(1,2-dicarbollido)-3-cobalt(1-)]ate ion. Syntheses, properties and structures of its 8,8′-mu-sulfato, 8-phenyl and 8-dioxane derivatives. *Collect. Czech. Chem. Commun.* **1997**, *62* (1), 47–56.

(44) Sivaev, I. B.; Bregadze, V. I. Chemistry of cobalt bis(dicarbollides). A review. *Collect. Czech. Chem. Commun.* **1999**, *64* (5), 783–805.

(45) Plešek, J.; Grüner, B.; Báča, J.; Fusek, J.; Císařová, I. Syntheses of the B-(8)-hydroxy- and B((8),(8)′)-dihydroxy-derivatives of the bis(1,2-dicarbollido)-3-colbalt(1-)ate ion by its reductive acetoxylation and hydroxylation: molecular structure of [8,8′-mu-CH3C(O)(2)(1,2-C2B9H10)(2)-3-Co](0) zwitterion determined by X-ray diffraction analysis. *J. Organomet. Chem.* **2002**, *649* (2), 181–190.

(46) Plešek, J.; Grüner, B.; Císařová, I.; Báča, J.; Selucký, P.; Rais, J. Functionalized cobalt bis(dicarbollide) ions as selective extraction reagents for removal of M2+ and M3+ cations from nuclear waste, crystal and molecular structures of the [8,8′-mu-CIP(O)(O)(2)(1,2-C2B9H10)(2)-3,3′-Co]HN(C2H5)(3) and [8,8′-mu-Et2NP(O)(O)(2) (1,2-C2B9H10)(2)-3,3′-Co](HN(CH3)(3)). *J. Organomet. Chem.* **2002**, *657* (1–2), 59–70.

(47) Matějíček, P.; Cígler, P.; Procházka, K.; Král, V. Molecular assembly of metallacarboranes in water: light scattering and microscopy study. *Langmuir* **2006**, *22* (2), 575–581.

(48) Matějíček, P.; Cígler, P.; Olejniczak, A. B.; Andrysiak, A.; Wojtczak, B.; Procházka, K.; Lesnikowski, Z. J. Aggregation behavior of nucleoside-boron cluster conjugates in aqueous solutions. *Langmuir* **2008**, *24* (6), 2625–2630.

(49) Semioshkin, A. A.; Sivaev, I. B.; Bregadze, V. I. Cyclic oxonium derivatives of polyhedral boron hydrides and their synthetic applications. *Dalton Trans.* **2008**, *8*, 977–992.

(50) Sivaev, I. B.; Bregadze, V. V. Polyhedral boranes for medical applications: current status and perspectives. *Eur. J. Inorg. Chem.* **2009**, *11*, 1433–1450.

(51) Rak, J.; Kaplánek, R.; Král, V. Solubilization and deaggregation of cobalt bis(dicarbollide) derivatives in water by biocompatible excipients. *Bioorg. Med. Chem. Lett.* **2010**, *20* (3), 1045–1048.

(52) Rak, J.; Jakubek, M.; Kaplánek, R.; Matějíček, P.; Král, V. Cobalt bis(dicarbollide) derivatives: solubilization and self-assembly suppression. *Eur. J. Med. Chem.* **2011**, *46* (4), 1140–1146.

(53) Fanfrlík, J.; Lepšík, M.; Horinek, D.; Havlas, Z.; Hobza, P. Interaction of carboranes with biomolecules: formation of dihydrogen bonds. *ChemPhysChem* **2006**, *7* (5), 1100–1105.

(54) Li, H. Y.; Shimizu, H.; Flinspach, M.; Jamal, J.; Yang, W. P.; Xian, M.; Cai, T. W.; Wen, E. Z.; Jia, Q. A.; Wang, P. G.; Poulos, T. L. The novel binding mode of *N*-alkyl-*N*′-hydroxyguanidine to neuronal

nitric oxide synthase provides mechanistic insights into NO biosynthesis. *Biochemistry* **2002**, *41* (47), 13868−13875.

(55) Flinspach, M.; Li, H. Y.; Jamal, J.; Yang, W. P.; Huang, H.; Silverman, R. B.; Poulos, T. L. Structures of the neuronal and endothelial nitric oxide synthase heme domain with D-nitroarginine-containing dipeptide inhibitors bound. *Biochemistry* **2004**, *43* (18), 5181−5187.

(56) Raman, C. S.; Li, H.; Martásek, P.; Král, V.; Masters, B. S.; Poulos, T. L. Crystal structure of constitutive endothelial nitric oxide synthase: a paradigm for pterin function involving a novel metal center. *Cell* **1998**, *95* (7), 939−50.

(57) Fischmann, T. O.; Hruza, A.; Niu, X. D.; Fossetta, J. D.; Lunn, C. A.; Dolphin, E.; Prongay, A. J.; Reichert, P.; Lundell, D. J.; Narula, S. K.; Weber, P. C. Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation. *Nat. Struct. Biol.* **1999**, *6* (3), 233−242.

(58) Crane, B. R.; Arvai, A. S.; Ghosh, D. K.; Wu, C. Q.; Getzoff, E. D.; Stuehr, D. J.; Tainer, J. A. Structure of nitric oxide synthase oxygenase dimer with pterin and substrate. *Science* **1998**, *279* (5359), 2121−2126.

(59) Martásek, P.; Liu, Q.; Liu, J. W.; Roman, L. J.; Gross, S. S.; Sessa, W. C.; Masters, B. S. S. Characterization of bovine endothelial nitric oxide synthase expressed in *E-coli*. *Biochem. Biophys. Res. Commun.* **1996**, *219* (2), 359−365.

(60) Roman, L. J.; Martásek, P.; Miller, R. T.; Harris, D. E.; de La Garza, M. A.; Shea, T. M.; Kim, J. J.; Masters, B. S. The C termini of constitutive nitric-oxide synthases control electron flow through the flavin and heme domains and affect modulation by calmodulin. *J. Biol. Chem.* **2000**, *275* (38), 29225−29232.

(61) Roman, L. J.; Miller, R. T.; de la Garza, M. A.; Kim, J. J. P.; Masters, B. S. S. The C terminus of mouse macrophage inducible nitric-oxide synthase attenuates electron flow through the flavin domain. *J. Biol. Chem.* **2000**, *275* (29), 21914−21919.

(62) Roman, L. J.; Sheta, E. A.; Martásek, P.; Gross, S. S.; Liu, Q.; Masters, B. S. S. High-level expression of functional-rat neuronal nitric-oxide synthase in *Escherichia-coli*. *Proc. Natl. Acad. Sci. U.S.A.* **1995**, *92* (18), 8428−8432.

(63) Zhang, M. J.; Vogel, H. J. Characterization of the calmodulin-binding domain of rat cerebellar nitric-oxide synthase. *J. Biol. Chem.* **1994**, *269* (2), 981−985.

(64) Hevel, J. M.; Marletta, M. A. Nitric-oxide synthase assays. *Methods Enzymol.* **1994**, *233*, 250−258.

(65) Connors, K. A. In *Binding Constants*; John Wiley & Sons: New York, 1981.

(66) Plešek, J.; Rajabi, F. H.; Vangani, V.; Fusek, J. Constitution and Properties of the 8,8(′)-Mu-H2no (1,2-C2b9h10)2-3-Co Bridged Cobaltaborane. *Collect. Czech. Chem. Commun.* **1994**, *59* (6), 1326−1336.

(67) Plešek, J.; Grüner, B.; Heřmánek, S.; Fusek, J.; Votavová, H. Constitution and HPLC resolution of enantiomers of the [8,4′-Mu-R2n-Commo-(1,2-C2b9h10)2-3-Co] complex: the 3rd isomer of nitrogen-bridged bisicosahedral cobaltacarborane. *Collect. Czech. Chem. Commun.* **1994**, *59* (2), 374−380.

(68) Plešek, J.; Heřmánek, S.; Baše, K.; Todd, L. J.; Wright, W. F. Zwitterionic compounds of 8,8′-X(C2B9H10)2Co series with monoatomic O, S, Se, Te, N bridges between carborane ligands. *Collect. Czech. Chem. Commun.* **1976**, *41* (12), 3509−3515.

(69) Janoušek, Z.; Plešek, J.; Heřmánek, S.; Baše, K.; Todd, L. J.; Wright, W. F. Synthesis and characteristics of sulfur interligand bridge-derivatives and of some S-substituted compounds in the (C2B9H11)-2Co-series: conformations of (C2B9H11)2Mx-metallocarboranes. *Collect. Czech. Chem. Commun.* **1981**, *46* (11), 2818−2833.

(70) Grüner, B.; Císařová, I.; Čáslavský, J.; Bonnetot, B.; Cornu, D. Synthesis of 12-hydroxy and 12-dioxane derivatives of the closo-1-carbadodecaborate(1−) ion. Variations on the Plesek's cobalt bis(dicarbollide) pattern. *Collect. Czech. Chem. Commun.* **2002**, *67* (7), 953−964.

(71) Holub, J.; Grüner, B.; Císařová, I.; Fusek, J.; Plzák, Z.; Teixidor, F.; Viñas, C.; Štíbr, B. A series of the twelve-vertex ferratricarbollides [2-(eta(5)-C5H5)-9-X-closo-2,1,7,9-FeC3B8H10] (where x = H2N, MeHN, Me2N, (BuHN)-H-t, Bu-t(Me)N). A highly stable metal-latricarbaborane system with amine functions in the para position to the metal center. *Inorg. Chem.* **1999**, *38* (12), 2775−2780.

(72) Hertler, W. R.; Raasch, M. S. Chemistry of Bboranes. 14. Amination of B10h10-2 + B12h12-2 with Hydroxylamine-*O*-sulfonic acid. *J. Am. Chem. Soc.* **1964**, *86* (18), 3661−3668.

(73) Grüner, B.; Bonnetot, B.; Mongeot, H. Synthesis of N- and B-substituted derivatives of closo-amino-undecahydro-dodecaborate(1−) anion. *Collect. Czech. Chem. Commun.* **1997**, *62* (8), 1185−1204.

(74) Sivaev, I. B.; Starikova, Z. A.; Sjöberg, S.; Bregadze, V. I. Synthesis of functional derivatives of the [3,3′-Co(1,2-C2B2H11)(2)] (−) anion. *J. Organomet. Chem.* **2002**, *649* (1−2), 1−8.

(75) Katritzky, A. R.; Rogovoy, B. V. Recent developments in guanylating agents. *ARKIVOC* **2005**, 49−87.

(76) Lee, Y. B.; Folk, J. E. Branched-chain and unsaturated 1,7-diaminoheptane derivatives as deoxyhypusine synthase inhibitors. *Bioorg. Med. Chem.* **1998**, *6* (3), 253−270.

(77) Kraus, T.; Budešínský, M.; Závada, J. Synthesis of per-6-guanidinylated cyclodextrins. *Tetrahedron Lett.* **2006**, *47* (5), 679−681.